Phase 2 Study of ALXN2030 in Patients with Antibody-Mediated Rejection after Kidney Transplantation
Study Identifier:
D8560C00002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2030
- Drug: Placebo
Date
Mar 2025 - Oct 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Sex
Female & Male
Age
18 - 75 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2030
- Drug: Placebo
Date
Mar 2025 - Oct 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Trial Locations
Location
Status
Location
Research Site
Richmond, VA, United States, 23298
Status
Not yet recruiting
Location
Research Site
Kaohsiung City, Unmapped, 813
Status
Recruiting
Location
Research Site
Taichung, Unmapped, 40705
Status
Recruiting
Location
Research Site
Seoul, Unmapped, 3722
Status
Recruiting
Location
Research Site
Sao Paulo, Unmapped, 05403-900
Status
Recruiting
Location
Research Site
Kansas City, KS, United States, 66160
Status
Not yet recruiting